A control group is the comparison group of a clinical trial against which the effect of an investigational intervention is assessed. It receives a control intervention defined in the protocol or, under certain conditions, no treatment. Its selection determines which clinical question the trial can answer and how meaningful an observed difference is.
Task of the comparison group
The control group establishes the reference point for the evaluation of efficacy and safety. It helps to distinguish changes under the investigational intervention from spontaneous courses, concomitant treatments, expectation effects, observational conditions or temporal influences. In a randomized parallel group trial, eligible participants are assigned to an investigational or control treatment; the concurrent conduct reduces differences that could arise solely from changes in care or diagnostics.
A control group is not only a methodological element, but part of the clinical and ethical justification of a protocol. The choice must be appropriate for the disease, the stage of development, available effective therapies, the expected effect size and the endpoints. ICH E10 requires the type of control to be justified based on the trial objectives and the knowledge about the disease as well as the intervention.
Control types according to ICH E10
ICH E10 distinguishes five basic types. A placebo-controlled parallel group receives a dummy preparation alongside the usual concomitant care, provided this is ethically and scientifically justifiable. In a no-treatment controlled trial, the control group receives no investigational intervention; this can be considered, for example, for objectively observable and stably measurable courses. Both are concurrent controls.
A dose-comparison control group receives a different dose or a different dosing regimen of the same intervention. It can investigate a dose-response relationship, but does not readily answer the question of an advantage over no treatment. In an active control trial, the investigational intervention is compared with another effective treatment. The selection of the active control, the dosage and the conduct must allow a meaningful conclusion.
ICH E10 refers to data outside the ongoing randomized comparative trial, such as historical data or data from registries, as an external control. Such comparisons are particularly susceptible to differences in population, diagnostics, follow-up and assessment. Therefore, they require a particularly careful justification and cannot generally replace a concurrent randomized control.
The choice of the control also influences the estimation of the treatment effect. A placebo comparison can elucidate the effect versus no specific treatment, while an active control addresses the question of a difference to an available therapy. Which conclusion is permissible therefore depends not only on a statistically observed difference, but on the entire comparison concept. Criteria for concomitant therapies, change of treatment and follow-up must be applied as equally as possible in both arms.
Consequently, the control group must not only be medically justifiable, but also suitable for the intended statement of the development program.
Distinction from placebo and comparator
The control group designates the entirety of the participants who are treated or observed according to the comparison arm. Placebo, on the other hand, is a possible control intervention. It is designed so that it does not contain the active ingredient, but can create a credible comparison condition. Not every control group receives a placebo: depending on the objective, it can remain untreated, receive a different dose or be treated with an active therapy.
The comparator is also not synonymous with the control group. It refers to the medicinal product or the intervention that is used in the control arm, for example an established therapy. The term control group refers to persons and study arm; comparator refers to the object of the treatment. In an active control trial, the comparator is part of the control strategy, not its complete description.
Relevance for clinical trials
The decision for a control type influences sample size, blindability, endpoint assessment, safety interpretation and the transferability of the results. Unsuitable comparison conditions can overestimate or underestimate an effect or leave the clinical significance of a difference open. The protocol, informed consent documents and statistical analysis plan must therefore consistently describe the control, concomitant treatments, rescue medication and the intended comparative statement.
Full-service CROs such as Mediconomics support with the development of a justified control strategy, with feasibility assessments of the investigational sites and with the preparation of protocol, randomization concept and statistical analysis plan. Regulatory affairs, medical writing, biostatistics, data management and monitoring coordinate the specifications for comparison arm, blinding, data collection and analysis.
Frequently Asked Questions (FAQ)
Can a control group receive no study medication?
Yes. A no-treatment controlled trial is a control type described by ICH E10, the suitability of which depends on the objective and ethical justifiability.
Is an active control always a standard therapy comparison?
Frequently, an effective established therapy is chosen. Crucial, however, is that selection, dosage and application enable an interpretable comparison.
Why are historical controls more difficult to evaluate?
Populations and observational conditions are not necessarily comparable. Differences can therefore erroneously appear as a treatment effect.
Regulatory references
- ICH E10 “Choice of Control Group and Related Issues in Clinical Trials” – systematizes control types and their meaning.
- ICH E8(R1) “General Considerations for Clinical Studies” – requires a study design tailored to the clinical question.
- Regulation (EU) No 536/2014 – regulates the authorization of clinical trials in the European Union.